For a study, the researchers sought to provide an improved and more comprehensive look at the epidemiology and prognosis of these rare malignancies. The data were obtained retrospectively from the United States’ Central Brain Tumor Registry (CBTRUS). Primary malignant non-osseous spinal tumor instances were diagnosed in the United States between 2000 and 2017. The researchers calculated the incidence rates (IRs), relative survival rates (RSRs), and hazard ratios (HRs). Between 2000 and 2017, IRs were determined exclusively for histologically confirmed patients. Between 2001 and 2016, survival data on malignant spinal tumors were used to create relative survival estimates for death from any cause. To account for age, sex, race, and ethnicity, multivariable Cox proportional hazards regression models were produced. Every year in the United States, around 587 new cases of malignant non-osseous spinal tumors were discovered between 2000 and 2017. The overall IR was 0.178 people per 100,000. In all age categories, ependymomas were the most often diagnosed tumor. For ependymomas, lymphomas, diffuse astrocytomas, and high-grade astrocytomas, the 10-year relative survival rates were 94.1%, 62.1%, 62.0%, and 13.3%, respectively. For ependymomas (HR: 0.74, P<.001) and diffuse astrocytomas (HR: 0.70, P=.005), females had a considerably reduced chance of death than males. When diagnosed with ependymomas (HR: 1.52, P=.009) or lymphomas (HR: 1.55, P=.009), African-Americans had a considerably higher risk of death than Caucasians. Adults and late adults were more likely to be diagnosed with primary malignant non-osseous spinal tumors. Ependymal tumors were the most prevalent primary malignant non-osseous spinal tumors, and they had the best 10-year survival rates. High-grade astrocytomas were uncommon and had a poor prognosis.